

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Herndon

FILED: July 9, 2001

SERIAL NO.: 09/901,429

FOR: β -Adrenergic Blockade Reversal
Of Catabolism After Severe Burn



§ ART UNIT: 1614

§ EXAMINER:
§ Kim, Vickie

§ DOCKET: D6414
§

The Assistant Commissioner of Patents
BOX NON-FEE AMENDMENT
Washington, DC 20231

RECEIVED

JUL 09 2002

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

TECH CENTER 1600/2900

Dear Sir:

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: The Assistant Commissioner of Patents, BOX NON-FEE AMENDMENT, Washington DC 20231.

- 1) Response under 37 CFR 1.111.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

COPY OF PAPERS
ORIGINALLY FILED

Date:

Jul 26, 2002

Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant

ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
(713) 270-5391
BADLER1@houston.rr.com

7-13
J03
3-2202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Herndon

FILED: July 9, 2001

SERIAL NO.: 09/901,429

FOR: β -Adrenergic Blockade Reversal
Of Catabolism After Severe Burn



§ ART UNIT: 1614

§ EXAMINER:
§ Kim, Vickie

§ DOCKET: D6414

Assistant Commissioner of Patents
BOX NON-FEE AMENDMENT
Washington, DC 20231

RECEIVED

JUL 09 2002

TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed June 19, 2002,
please enter the following amendments and remarks.
Reconsideration of the pending claims is respectfully requested.

AMENDMENTS

COPY OF PAPERS
ORIGINALLY FILED

IN THE CLAIMS:

Please amend claim 1 as follows:

B.I. 1. (twice amended) A method of treating an individual
having a severe burn, comprising the step of administering to said
individual a pharmacologically effective dose of a beta-adrenergic
antagonist, wherein treatment with said beta-adrenergic antagonist

G